Research programme: anticancer therapeutics - Provid/NCI
Latest Information Update: 04 Apr 2008
At a glance
- Originator National Cancer Institute (USA)
- Developer National Cancer Institute (USA); Provid Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Oct 2005 Preclinical trials in Cancer in USA (unspecified route)